Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Drug Approvals and Databases

Drug Approvals and Databases

                        


                        Resources for Information | Approved Drugs Home
          Drugs
          Development & Approval Process | Drugs
          Drug Approvals and Databases
          Drug Trials Snapshots: INMAZEBDrug Approvals and Databases Drug Trials Snapshots: INMAZEB
  
  	
    Share
    Post
    Linkedin

    Email
    Print**HOW TO USE THIS SNAPSHOT**
The information provided in Snapshots highlights who participated in the clinical trials that supported the FDA approval of this drug, and whether there were differences among sex, race and age groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

**LIMITATIONS OF THIS SNAPSHOT**
Do not rely on Snapshots to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of a drug. Refer to the I*NMAZEB Package Insert* for complete information.


**INMAZEB** (atoltivimab, maftivimab, and odesivimab-ebgn)
ihn-ma-zehb
Regeneron
Approval date: October 14, 2020

DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

INMAZEB is a drug used to treat pediatric and adult patients who have an infection caused by *Zaire ebolavirus*.

*Zaire ebolavirus* infection (sometimes called Ebola or Ebola virus disease) is a rare, contagious, rapidly progressive and often deadly disease.

How is this drug used?

INMAZEB is an injection. It is given one time by a healthcare provider directly into the vein (intravenous infusion). The amount of the drug to be administered is based on the patient’s weight.

What are the benefits of this drug?

INMAZEB lowered the risk of dying from the infection. Out of 154 patients treated with INMAZEB, 52 patients (34%) died within 28-days in comparison to 78 out the 153 patients (51%) who were treated with another experimental drug.

MORE INFO
	**What are the benefits of this drug (results of trials used to assess efficacy)?**

The table below summarizes the efficacy results for a pre-specified interim analysis of 28-day mortality. The table includes only the patients randomized and eligible to receive either INMAZEB or the control during the same time period of the trial. Treatment assignments were randomized within separate subgroups determined by the baseline laboratory test for Zaire ebolavirus infection corresponding to either a high viral load (CtNP ≤ 22.0) or a low viral load (CtNP ˃22.0).

**Table 1. Mortality Rates in Trial 1**

Efficacy Endpoints
			INMAZEBa
			(N=154)
			Controla
			(N=153)Overall28-day mortality, n (%)
			52 (34%)
			78 (51%)Mortality rate difference relative to control (95% CI)
			-17.2 (-28.4, -2.6)p-Valueb
			0.0024Baseline Viral LoadHigh viral load (CtNP ≤ 22)c
			n=66
			n=6428-day mortality, n (%)
			42 (64%)
			56 (88%)Mortality rate difference relative to control (95% CI)
			-23.9 (-43.8, -6.4)Low viral load (CtNP > 22)c
			n=88
			n=8828-day mortality, n (%)
			10 (11%)
			22 (25%)Mortality rate difference relative to control (95% CI)
			-13.6 (-31.8, -1.4)

a Both INMAZEB and Control were administered with optimized standard of careb The result is significant according to the interim stopping boundary, p<0.028c Cepheid GeneXpert Ebola® Assay used for detection of Zaire ebolavirus RNA

INMAZEB Prescribing Information

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

**Sex:** INMAZEB worked similarly in males and females.
	**Race:** Data not collected.
	**Age:** INMAZEB worked similarly in all tested age groups.MORE INFO
	**Were there any differences in how well the drug worked in clinical trials among sex, race, and age groups?**

The table below summarizes primary efficacy results by sex and age subgroups.

**Table 2. 28-Day Mortality Rates**

Subgroup
			INMAZEB
			(N=154)
			Control
			(N=153)SexMale
			21/64 (33%)
			31/73 (42%)Female
			31/90 (34%)
			47/80 (59%)Age group< 6 years of age
			10/23 (43%)
			6/16 (38%)6 to < 12 years of age
			1/8 (13%)
			1/4 (25%)12 to < 18 years of age
			2/8 (25%)
			4/8 (50%)Adults (age ≥18 years)
			39/115 (34%)
			67/125 (54%)

INMAZEB Prescribing Information

What are the possible side effects?

INMAZEB may cause serious side effects including severe and life-threatening allergic reactions during and after the infusion.

The most common side effects of INMAZEB are fever, chills, fast heart rate, fast breathing and vomiting.

MORE INFO
	What are the possible side effects?

The table below summarizes adverse events that were reported during INMAZEB infusion. This table includes all patients who received either INMAZEB or the control throughout the trial.

**Table 3. Adverse Events That Occurred during INMAZEB Infusion in ≥10% of Adult and Pediatric Subjects in the Trial**

Adverse Eventa
			INMAZEB
			(N=154)
			%
			Controlc
			(N=168)
			%Pyrexia (Elevation in fever)
			54
			58Chills
			39
			33Tachycardia
			20
			32Tachypnea
			19
			28Vomitingb
			19
			23Hypotension
			15
			31Diarrheab
			11
			18Hypoxiab
			10
			11

a Adverse events in this table were reported as preferred terms from a list of pre-defined or other adverse events that occurred on the day of infusion, and included signs and symptoms that occurred during or immediately after infusionb Adverse events that were not pre-specifiedc Investigational therapy administered as three separate infusions

INMAZEB Prescribing Information

Were there any differences in side effects among sex, race and age?

**Sex:** The occurrence of side effects was similar in males and females.
	**Race:** Data not collected.
	**Age:** The occurrence of side effects was similar in all tested groups.MORE INFO
	Were there any differences in side effects of the clinical trials among sex, race, and age groups?

The table below summarizes the occurrence of the most frequent adverse events by sex and age subgroups. Demographic information for race was not collected.

**Table 4. Subgroup Analysis of Adverse Events by Sex**

Adverse Event
			INMAZEB
			N=154
			Control
			N=168Male
			N=63
			%
			Female
			N=91
			%
			Male
			N=82
			%
			Female
			N=86
			%Any adverse event
			78
			78
			90
			87Pyrexia
			51
			56
			65
			51Chills
			38
			39
			40
			26Tachycardia
			22
			19
			27
			36Tachypnea
			21
			19
			28
			27Vomiting
			14
			23
			26
			20Hypotension
			13
			17
			26
			36Diarrhea
			14
			9
			22
			15

Clinical Trial Data

**Table 5. Subgroup Analysis of Adverse Events by Age**

INMAZEB
			N=154
			Control
			N=168Adverse Event
			Age <6
			N=24
			%
			Age 6-11
			N=7
			%
			Age 12-17
			N=8
			%
			Age ≥18
			N=115
			%
			Age <6
			N=19
			%
			Age 6-11
			N=5
			%
			Age 12-17
			N=8
			%
			Age ≥18
			N=136
			%Any adverse event
			79
			86
			63
			78
			84
			80
			100
			89Chills
			21
			43
			-
			44
			11
			20
			50
			35Pyrexia
			54
			43
			13
			57
			74
			40
			63
			56Tachycardia
			38
			-
			-
			19
			21
			20
			38
			33Tachypnea
			21
			29
			-
			20
			26
			20
			25
			28Vomiting
			21
			14
			25
			19
			21
			-
			38
			23Hypotension
			13
			14
			25
			15
			16
			20
			38
			33Diarrhea
			4
			14
			13
			12
			16
			40
			13
			18

Clinical Trial Data

WHO WAS IN THE CLINICAL TRIALS?

Who participated in the trials?

The FDA approved INMAZEB based primarily on evidence from a clinical trial (Trial 1/ NCT NCT03719586) of 322 patients with Zaire ebolavirus infection. The trial was conducted at four sites in the Democratic Republic of Congo during an outbreak that began in August 2018.

Figure 1 summarizes how many males and females were in the clinical trial.

**Figure 1. Demographics by Sex (safety population)**

Pie chart summarizing how many males and females were in the clinical trials. In total, 145 males (45%) and 177 females (55%) participated in the clinical trial.
Clinical Trial Data

**Baseline Demographics by Race - data not collected.**

Figure 2 summarizes the percentage of patients by age.

**Figure 2. Demographics by Age (safety population)**

Pie chart summarizing how many individuals of certain age groups were in the clinical trial.  In total, 43 patients were less than 6 years old (13%), 12 patients were between 6-11 years old (4%), 16 patients were between 12-17 years old (5%), and 251 patients were 18 years and older (78%).
Clinical Trial Data

**Demographics by Ethnicity - data not collected.**

MORE INFO
	Who participated in the trials?

The table below summarizes demographics of patients in the trial.

**Table 6. Demographic Characteristics (safety population)**

Demographic Characteristic
			INMAZEB
			N=154
			Control
			N=168
			TOTAL
			N=322SexMale
			63 (41 %)
			82 (49 %)
			145 (45 %)Female
			91 (59 %)
			86 (51 %)
			177 (55 %)Race (not collected)Age (years)Median
			26
			27.5
			27Min, Max
			<1, 73
			<1, 70
			<1, 73Age Group<6 years
			24 (16 %)
			19 (11 %)
			43 (13 %)6-11 years
			7 (4 %)
			5 (3 %)
			12 (4 %)12-17 years
			8 (5 %)
			8 (5 %)
			16 (5 %)≥18 years
			115 (75 %)
			136 (81 %)
			251 (78 %)Ethnicity (not collected)Geographic RegionUS
			0
			0
			0Democratic Republic of Congo
			154 (100 %)
			168 (100 %)
			322 (100 %)

Clinical Trial Data

How were the trials designed?

There was one trial that evaluated both, benefits and side effects of INMAZEB. The trial enrolled pediatric and adult patients (including pregnant women) with Zaire ebolavirus infection. All patients received standard, supportive care for the disease. In addition to the standard care, patients were randomly assigned to receive either a one-time dose of INMAZEB or one of the three other types of experimental treatments (including one as the control group). The patients and the health care providers knew which treatment was being given.

The benefit was evaluated by comparing the proportion of patients who died within 28 days from their trial enrollment in the INMAZEB-treated group to the patients who received the control treatment.

MORE INFO
	How were the trials designed?

The safety and efficacy of INMAZEB were established in a multi-center, open label, randomized active-controlled trial. The trial evaluated pediatric and adult patients (including pregnant women) who acquired Zaire ebolavirus infection. All patients received an optimized standard of care. In addition, patients were randomized to receive a single infusion of INMAZEB, an investigational control intravenously every third day, totaling 3 doses, or other investigational drug.

The primary efficacy endpoint was 28-day mortality. The primary analysis population included all subjects who were randomized and concurrently eligible to receive either INMAZEB or the investigational control during the same time period of the trial.

GLOSSARY

**CLINICAL TRIAL:** Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.**COMPARATOR:** A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.**EFFICACY:**How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.**PLACEBO:**An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.**SUBGROUP:**A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

PRESCRIBING INFORMATION

Back to Drug Trials Snapshots

                                                                                  Content current as of:
      10/22/2020
              
              
Regulated Product(s)
		 DrugsDrug Approvals and Databases

          
                        


                        Resources for Information | Approved Drugs
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop